Insider Selling: GeneDx (NASDAQ:WGS) CEO Sells $2,001,331.99 in Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 25,459 shares of the business’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $78.61, for a total value of $2,001,331.99. Following the transaction, the chief executive officer directly owned 38,683 shares of the company’s stock, valued at approximately $3,040,870.63. This represents a 39.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Katherine Stueland also recently made the following trade(s):

• On Thursday, January 29th, Katherine Stueland sold 1,653 shares of GeneDx stock. The shares were sold at an average price of $94.00, for a total transaction of $155,382.00.
• On Tuesday, December 16th, Katherine Stueland sold 10,857 shares of GeneDx stock. The stock was sold at an average price of $143.89, for a total transaction of $1,562,213.73.
• On Tuesday, December 9th, Katherine Stueland sold 3,639 shares of GeneDx stock. The stock was sold at an average price of $159.28, for a total transaction of $579,619.92.

GeneDx Trading Up 7.5%

Shares of NASDAQ:WGS opened at $88.11 on Friday. GeneDx Holdings Corp. has a 52 week low of $55.17 and a 52 week high of $170.87. The company’s 50 day moving average is $100.80 and its two-hundred day moving average is $122.17. The company has a current ratio of 2.46, a quick ratio of 2.34 and a debt-to-equity ratio of 0.16. The company has a market cap of $2.58 billion, a PE ratio of -117.48 and a beta of 2.03.

GeneDx (NASDAQ:WGS) last announced its quarterly earnings data on Monday, February 23rd. The company reported $0.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.11 by $0.03. The business had revenue of $120.99 million for the quarter, compared to analyst estimates of $120.80 million. GeneDx had a negative net margin of 4.92% and a positive return on equity of 14.73%. Equities analysts predict that GeneDx Holdings Corp. will post 0.97 earnings per share for the current fiscal year.

Institutional Trading of GeneDx

A number of large investors have recently made changes to their positions in the company. Arizona State Retirement System grew its stake in GeneDx by 2.1% during the 4th quarter. Arizona State Retirement System now owns 5,594 shares of the company’s stock worth $728,000 after buying an additional 113 shares during the last quarter. Cerity Partners LLC boosted its holdings in shares of GeneDx by 6.0% in the fourth quarter. Cerity Partners LLC now owns 2,527 shares of the company’s stock valued at $329,000 after acquiring an additional 142 shares during the period. Main Management ETF Advisors LLC grew its position in shares of GeneDx by 1.0% during the fourth quarter. Main Management ETF Advisors LLC now owns 15,660 shares of the company’s stock worth $2,037,000 after acquiring an additional 160 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of GeneDx by 5.1% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,702 shares of the company’s stock worth $399,000 after acquiring an additional 181 shares during the last quarter. Finally, Jones Financial Companies Lllp increased its holdings in shares of GeneDx by 664.3% in the 3rd quarter. Jones Financial Companies Lllp now owns 214 shares of the company’s stock valued at $25,000 after acquiring an additional 186 shares during the period. 61.72% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. Weiss Ratings reaffirmed a “sell (d)” rating on shares of GeneDx in a report on Wednesday, January 21st. Jefferies Financial Group set a $150.00 target price on GeneDx in a research note on Monday, February 23rd. Wall Street Zen lowered shares of GeneDx from a “buy” rating to a “hold” rating in a research note on Sunday, February 8th. Canaccord Genuity Group boosted their price objective on shares of GeneDx from $160.00 to $170.00 and gave the stock a “buy” rating in a research report on Monday, December 22nd. Finally, BTIG Research lowered their target price on shares of GeneDx from $200.00 to $170.00 and set a “buy” rating for the company in a report on Tuesday, February 24th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $150.71.

GeneDx News Roundup

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Large affiliated/institutional buy: Corvex Management reported a purchase of GeneDx shares worth roughly $13.4 million, a strong signal of institutional confidence that can support the stock. Corvex management buys GeneDx (WGS) shares worth $13.4 million
• Positive Sentiment: Director buying: Director Keith A. Meister made two recent purchases (140,026 shares on Mar 5 at ~$81.19 and 29,495 shares on Mar 3 at ~$70.89), increasing his stake to over 3.2M shares — a large insider accumulation that typically signals confidence and can drive demand. SEC ownership filing — Keith A. Meister purchases
• Positive Sentiment: Recent earnings beat: GeneDx topped consensus on its most recent quarterly EPS and delivered revenue roughly in line with estimates, supporting a bullish narrative around recurring revenue and margin progress (analyst consensus remains a Moderate Buy with elevated price targets).
• Neutral Sentiment: Short-interest reading shows 0 reported short interest as of Mar 5, which appears to be a data anomaly and offers little actionable signal on immediate directional pressure.
• Negative Sentiment: CEO sale: CEO Katherine Stueland sold 25,459 shares on Mar 4 (~$2.0M) and cut her direct stake materially. Significant insider sales can worry some investors about insiders taking liquidity. SEC Form 4 — CEO sale
• Negative Sentiment: CFO sale: CFO Kevin Feeley sold 6,187 shares on Mar 4 (~$486k), trimming his position by roughly 25%; this adds to mixed insider signals even though the size is smaller than the institutional buys. SEC Form 4 — CFO sale

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.